(P016) The Cell Cycle Inhibitor P21 Regulates Langerhans Cell Radiation Resistance and PromotesT Regulatory Cell Induction Upon Exposure to Radiotherapy

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Future analyses will seek to elaborate the functional implications of LCs and IR-sensitive DC IR-exposure as it relates to the priming and development of graft-versus-host disease (GVHD) and local antitumor immunity following radiation therapy.

Jeremy G. Price, Juliana Idoyaga, Brandon Hogstad, Helene Salmon, Marylene Leboeuf, Miriam Merad; Icahn School of Medicine at Mount Sinai; Stanford University

Several studies have revealed that exposure to ionizing irradiation (IR) may lead to increased accumulation of tumor-infiltrating T regulatory cells (Tregs), which in turn promotes tumor resistance to radiation therapy. Here, we questioned the contribution of tissue-resident antigen-presenting cells (APCs) to the induction of Tregs upon exposure to IR. Specifically, we focused on Langerhans cells (LCs), the resident APCs of the epidermis, because of their unique ability to resist depletion by high-dose IR. Therefore, LC IR resistance may inform us of the underlying IR resistance mechanisms utilized by other progenitor cells. However, a comprehensive study of the molecular and cellular mechanisms conferring LC IR resistance has never been undertaken.

We found that LCs do not undergo apoptosis following IR as do other dendritic cell (DC) subsets but instead persist and migrate to skin-draining lymph nodes. Subsequent analysis in migration-deficient CCR7−/− mice revealed a constant number of epidermal LCs, indicating that changes in LC number following IR are due solely to migration and not to cell death. Moreover, we show for the first time that LCs are resistant to the formation of DNA damage, as measured by induction of H2AX foci and COMET assay. In contrast, other members of the myeloid lineage, notably lymphoid tissue-resident DCs, are exquisitely sensitive to IR-induced DNA damage. In addition, both steady-state and postlethal IR LCs express a unique repertoire of prosurvival and stress-related proteins and diminished levels of proapoptotic molecules by microarray analysis. Additionally, we found that the cell cycle regulator p21 is overexpressed in LCs at rest and that in contrast to WT LCs, p21−/− LCs undergo apoptosis, accumulate significant DNA damage, and fail to experience cell cycle arrest following IR. Strikingly, upon skin exposure to IR, WT LCs lead to significant expansion of Treg, whereas p21−/− LCs fail to do so. In a cutaneous tumor model, we show that p21−/− LCs cannot promote tumor-infiltrating Tregs and correlate with smaller tumor volumes.

Moving forward, these data suggest a novel means by which targeting LC IR resistance can be used to increase the response to radiotherapy of cutaneous tumors. LCs uniquely express an IR resistance module of genes that permits them to persist and repopulate the epidermal niche following IR. Future analyses will seek to elaborate the functional implications of LCs and IR-sensitive DC IR-exposure as it relates to the priming and development of graft-versus-host disease (GVHD) and local antitumor immunity following radiation therapy.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Related Content